PIK3CA and neoplasm: Serial plasma specimens collected from 30 women with ABC receiving systemic therapy were analyzed for ctDNA to monitor tumor burden using assays that were designed to detect somatic genomic alterations (including point mutations in PIK3CA and TP53) previously identified using targeted or whole genome sequencing.